US20070166325A1 - West Nile vaccine - Google Patents
West Nile vaccine Download PDFInfo
- Publication number
- US20070166325A1 US20070166325A1 US11/589,516 US58951606A US2007166325A1 US 20070166325 A1 US20070166325 A1 US 20070166325A1 US 58951606 A US58951606 A US 58951606A US 2007166325 A1 US2007166325 A1 US 2007166325A1
- Authority
- US
- United States
- Prior art keywords
- vaccine
- virus
- west nile
- composition
- tcid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 100
- 241000710886 West Nile virus Species 0.000 claims abstract description 75
- 241000283086 Equidae Species 0.000 claims abstract description 73
- 239000000203 mixture Substances 0.000 claims abstract description 70
- 239000002671 adjuvant Substances 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000013612 plasmid Substances 0.000 claims abstract description 13
- 230000003053 immunization Effects 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 241000700605 Viruses Species 0.000 claims description 50
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 16
- 241000283073 Equus caballus Species 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 229920001400 block copolymer Polymers 0.000 claims description 8
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 229940032094 squalane Drugs 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 239000002270 dispersing agent Substances 0.000 claims description 7
- 239000002736 nonionic surfactant Substances 0.000 claims description 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 7
- 238000009736 wetting Methods 0.000 claims description 7
- 239000000080 wetting agent Substances 0.000 claims description 7
- 201000006449 West Nile encephalitis Diseases 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- -1 polyoxyethylene Polymers 0.000 claims description 5
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 4
- 229960000814 tetanus toxoid Drugs 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 229940124856 vaccine component Drugs 0.000 claims description 3
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims description 2
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 claims description 2
- 241000701089 Equid alphaherpesvirus 4 Species 0.000 claims description 2
- 241000230501 Equine herpesvirus sp. Species 0.000 claims description 2
- 241000604972 Neorickettsia risticii Species 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- 241000194048 Streptococcus equi Species 0.000 claims description 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 2
- 241000710951 Western equine encephalitis virus Species 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 206010014599 encephalitis Diseases 0.000 abstract description 3
- 239000003921 oil Substances 0.000 description 31
- 235000019198 oils Nutrition 0.000 description 31
- 238000012360 testing method Methods 0.000 description 23
- 238000002255 vaccination Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 206010058874 Viraemia Diseases 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 241000255925 Diptera Species 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 5
- 229940033663 thimerosal Drugs 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- 108010041986 DNA Vaccines Proteins 0.000 description 4
- 229940021995 DNA vaccine Drugs 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- SGPYLFWAQBAXCZ-RUDZPDEXSA-N polymyxin B2 Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCCC(C)C)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 SGPYLFWAQBAXCZ-RUDZPDEXSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010057293 West Nile viral infection Diseases 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940001442 combination vaccine Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000256113 Culicidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000619564 Homo sapiens Putative testis-specific prion protein Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102100022208 Putative testis-specific prion protein Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 206010042364 Subdural haemorrhage Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to safe and effective West Nile Virus vaccines, and to methods of administering same to mammals, in particular horses.
- Flavivirus Known as a Flavivirus, the West Nile virus was first identified in 1937 in Africa and first found in North America in 1999. Migratory birds are considered the primary means whereby infection is spread within and between countries. The virus is transmitted by mosquitoes that have acquired infection by feeding on viremic birds. The virus is then amplified during periods of adult mosquito blood-feeding. Infected mosquitos then transmit the virus to humans and animals upon feeding thereon.
- West Nile virus is the causative agent for West Nile Virus disease, particularly West Nile encephalitis, predominately in humans, other mammals and birds.
- the chief concern in both the United States and foreign countries is the lack of effective treatment for West Nile virus disease.
- Anti-inflammatory drugs are used to combat swelling of central nervous system tissues, but beyond that no medical intervention is available.
- the vaccine composition should be sufficiently safened so as to be suitable for administration even to pregnant mares without adverse effect.
- the present invention provides a safened vaccine composition which comprises: an effective immunizing amount of an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, and a mixture thereof; an immunogenically stimulating amount of a metabolizable oil; and a pharmacologically acceptable carrier.
- an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, and a mixture thereof.
- the present invention also provides a method for the prevention or amelioration of West Nile encephalitis in equidae which comprises administering to said equidae a safened vaccine composition which comprises an effective immunizing amount of an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, and a mixture thereof; an immunogenically stimulating amount of a metabolizable oil; and a pharmacologically acceptable carrier.
- an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, and a mixture thereof
- an immunogenically stimulating amount of a metabolizable oil and a pharmacologically acceptable carrier.
- a safe and effective West Nile Virus vaccine suitable for use in horses which comprises an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, and a mixture thereof; an immunogenically stimulating amount of a metabolizable oil; and a pharmacologically acceptable carrier.
- the invention describes a vaccine composition
- a vaccine composition comprising at least about at least about 1 ⁇ 10 4 TCID 50 per unit dose of inactivated West Nile virus, or a component thereof, and about 4% to 10% vol/vol of a metabolizable oil comprising about 1 to 3% polyoxyethylene-polyoxypropylene block copolymer, about 2 to 6% of squalane and about 0.1 to 0.5% of polyoxyethylene sorbitan monooleate.
- a safened and effective West Nile virus vaccine for equidae comprising at least about 1 ⁇ 10 6 TCID 50 per unit dose of killed or inactivated West Nile virus, and at least about 1% vol/vol of an adjuvant comprising at least one metabolizable oil and at least one wetting or dispersing agent.
- the invention also sets forth a vaccine regimen for horses, comprising two dosage units of killed or inactivated West Nile virus, wherein each said dosage unit comprises about 0.5 to 5 milliliters of a composition containing at least about 5 ⁇ 10 7 TCID 50 of said virus and about 1 to 10% vol/vol of an adjuvant, said adjuvant comprising at least one metabolizable oil and at least two nonionic surfactants, and further wherein said dosage unit comprises a pharmacologically acceptable carrier.
- an equine vaccine containing West Nile plasmid DNA in an amount of about 50 to 3,000 micrograms per dose, together with one or more adjuvants and a suitable carrier.
- a vaccine regimen would comprise administering at least about one dose of this composition, and desirably at least about 2 doses, to horses for immunization against West Nile virus disease.
- a safe and effective vaccine composition which comprises an effective immunizing amount of an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, plasmid West Nile virus DNA, plasmid with sequence inserts of said virus, and a mixture thereof; an immunogenically stimulating amount of an adjuvant, in particular a metabolizable oil; and a pharmacologically acceptable carrier may be administered to equidae, particularly horses, to prevent or ameliorate West Nile Virus disease such as encephalitis.
- an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, plasmid West Nile virus DNA, plasmid with sequence inserts of said virus, and a mixture thereof
- an immunogenically stimulating amount of an adjuvant in particular a metabolizable oil
- DNA derived from the West Nile virus may be obtained via isolation from sources such as the fluids or tissues of equine or avian species diagnosed to have West Nile encephalitis. Such sources include cerebral spinal fluid or sections of spinal cord or brain. DNA may also be obtained using other available techniques such as plasmid technology. For example, suitable cells of an organism, e.g. E. coli , may be transformed with a plasmid containing West Nile protein sequence inserts to obtain a master seed. The master seed may then be cultured and passaged. Transformed cells containing the West Nile DNA may then be harvested, and the DNA isolated and obtained using techniques available to the skilled artisan.
- sources such as the fluids or tissues of equine or avian species diagnosed to have West Nile encephalitis. Such sources include cerebral spinal fluid or sections of spinal cord or brain. DNA may also be obtained using other available techniques such as plasmid technology. For example, suitable cells of an organism, e.g. E. coli , may be transformed with a plasmi
- Whole or subunit West Nile virus may be isolated from infected animals using conventional techniques. Samples of the virus may also be obtained from tissue culture collections which maintain a depository for organisms such as West Nile. At the American Type Culture Collection (ATCC), for example, the West Nile virus has been deposited under ATCC No.s VR-82, VR-1267 and VR-1267 AF.
- ATCC American Type Culture Collection
- Whole or subunit West Nile virus may be inactivated by conventional inactivating means, for example chemical inactivation using chemical inactivating agents such as binary ethyleneimine, beta-propiolactone, formalin, gluteraldehyde, sodium dodecyl sulfate, or the like or a mixture thereof, preferably formalin.
- Said virus may also be inactivated by heat or psoralen in the presence of ultraviolet light.
- Live, attenuated West Nile virus may also be used in certain embodiments, but this is perhaps much less preferred.
- Whole or subunit West Nile virus may be maintained or grown in mouse brains or in suitable tissue culture media, such as optiMEM (LTI, Grand Island, N.Y.) or MEM media, or in cells known in the art such as African green monkey kidney (Vero) cells or baby hamster (BHK) cells, preferably Vero cells. Said virus may then be separated from the tissue culture or cell media using conventional techniques such as centrifugation, filtration or the like.
- a preferred West Nile virus isolate may be obtained from the National Veterinary Services Laboratory (part of the United States Department of Agriculture) in Ames, Iowa as strain VM-2.
- the virus strain may be plaque purified up to three times, and passaged to X+5 in Vero cells.
- immunologically active designates the ability to stimulate an immune response, i.e., to stimulate the production of antibodies, particularly humoral antibodies, or to stimulate a cell-mediated response.
- an immune response i.e., to stimulate the production of antibodies, particularly humoral antibodies, or to stimulate a cell-mediated response.
- the effective immunizing amount of the immunogenically active component may vary and may be any amount sufficient to evoke an immune response and provide immunological protection against West Nile Virus disease. Amounts wherein a dosage unit comprises at least about 1 ⁇ 10 4 TCID 50 of killed or inactivated whole or subunit virus cells or antigen or DNA cells derived therefrom or a mixture thereof, preferably at least about 1 ⁇ 10 6 TCID 50 , are suitable. Even more preferably, at least about 1 ⁇ 10 7 TCID 50 per dosage unit may be utilized. It is especially desirable that at least about 5 ⁇ 10 7 TCID 50 of killed or inactivated whole or subunit West Nile virus cells or antigen or DNA cells derived therefrom or a mixture thereof be used in the vaccine composition of the invention. In certain embodiments, as much as 1 ⁇ 10 9 TCID 50 and more may be utilized. A range of about 1 ⁇ 10 4 TCID 50 to about 1 ⁇ 10 8 TCID 50 may also be utilized.
- plasmid DNA may be utilized in one dosage unit of the vaccine composition. More preferably, about 100 to 1,000 ⁇ g may be used, with about 100 to 250 ⁇ g of plasmid DNA being more preferred.
- At least one dosage unit per animal is contemplated herein as a vaccination regimen.
- two or more dosage units may be especially useful.
- a dosage unit may typically be about 0.1 to 10 milliliters of vaccine composition, preferably about 0.5 to 5 milliliters, and even more preferably about 1 to 2 milliliters, with each dosage unit containing the heretofore described quantity of virus or virus component.
- the skilled artisan will quickly recognize that a particular quantity of vaccine composition per dosage unit, as well as the total number of dosage units per vaccination regimen, may be optimized, so long as an effective immunizing amount of the virus or a component thereof is ultimately delivered to the animal.
- the West Nile virus vaccine composition of the invention may also contain one or more adjuvants.
- adjuvant refers to any component which improves the body's response to a vaccine.
- the adjuvant will typically comprise about 0.1 to 50% vol/vol of the vaccine formulation of the invention, more preferably about 1 to 50% of the vaccine, and even more desirably about 1 to 20% thereof. Amounts of about 4 to 10% may be even more preferred.
- Suitable adjuvants can include immunostimulating oils such as certain metabolizable oils.
- Metabolizable oils suitable for use in the composition of the invention include oil emulsions, e.g., SP oil (hereinafter described), Emulsigen (MPV Laboratories, Ralston, NZ), Montanide 264,266,26 (Seppic SA, Paris, France), as well as peanut oil and other vegetable-based oils, squalane (shark liver oil) or other metabolizable oil which can be shown to be suitable as an adjuvant in veterinary vaccine practice.
- the adjuvant may include one or more wetting or dispersing agents in amounts of about 0.1 to 25%, more preferably about 1 to 10%, and even more preferably about 1 to 3% by volume of the adjuvant.
- wetting or dispersing agents are non-ionic surfactants.
- Useful non-ionic surfactants include polyoxyethylene/polyoxypropylene block copolymers, especially those marketed under the trademark PLURONIC® and available from BASF Corporation (Mt. Olive, N.J.).
- Other useful nonionic surfactants include polyoxyethylene esters such as polyoxyethylene sorbitan monooleate, available under the trademark TWEEN 80®. It may be desirable to include more than one, e.g. at least two, wetting or dispersing agents in the adjuvant as part of the vaccine composition of the invention.
- compositions of the adjuvant may include such preservative compounds as formalin and thimerosal in amounts of up to about 1% vol/vol of the adjuvant.
- SP oil As an adjuvant, SP oil is preferred.
- SP oil designates an oil emulsion comprising a polyoxyethylene-polyoxypropylene block copolymer, squalane, polyoxyethylene sorbitan monooleate and a buffered salt solution.
- the SP oil emulsion will comprise about 1 to 3% vol/vol of block copolymer, about 2 to 6% vol/vol of squalane, more particularly about 3 to 6% of squalane, and about 0.1 to 0.5% vol/vol of polyoxyethylene sorbitan monooleate, with the remainder being a buffered salt solution.
- immunogenically stimulating amounts of SP oil as adjuvant in the vaccine composition of the invention may vary according to the immunogenically active component, the degree of potential infectious exposure, method of administration of the vaccine composition, the age and size of the equid, or the like. In general, amounts of about 1% to 50% vol/vol, preferably about 4% to 10% vol/vol, and more preferably about 4% to 5% vol/vol of SP oil are suitable.
- a live virus vaccine may potentially lack sufficient safety in a given target host, and that a killed or inactivated virus vaccine may potentially lack the ability to stimulate a sufficiently effective immunologic response.
- an adjuvant or immunogenically stimulating compound is used in combination with a killed or inactivated virus in a vaccine composition to obtain acceptable efficacy.
- safety to the target host is often compromised by the addition of an adjuvant.
- pregnant animals many times have been known to have a significantly higher rate of miscarriage after being administered a killed or inactivated virus vaccine that contains an adjuvant.
- the resultant West Nile vaccine composition is safened for use in equidae, particularly horses, even for use in pregnant mares, while demonstrating important efficacy as well.
- a suitable adjuvant e.g. a metabolizable oil preferably such as SP oil
- the resultant West Nile vaccine composition is safened for use in equidae, particularly horses, even for use in pregnant mares, while demonstrating important efficacy as well.
- the invention achieves the concomitant goals of effective immunization and safety, especially for pregnant animals. This combination of active immunogen and adjuvant is unheralded in the art.
- Pharmacologically acceptable carriers suitable for use in the vaccine composition of the invention may be any conventional liquid carrier suitable for veterinary pharmaceutical compositions, preferably a balanced salt solution or other water-based solution suitable for use in tissue culture media. Other available carriers may also be utilized.
- pH modifiers may be utilized.
- compositions of the invention as heretofore described including the carrier, may be combined together using available techniques.
- the vaccine composition of the invention may also contain other active components such as an antipathogenic component directed against rabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, equine herpes virus such as EHV-1 or EHV4, Ehrlichia risticii, Streptococcus equi , tetanus toxoid, equine influenza virus (EIV), or the like or a combination thereof.
- active components such as an antipathogenic component directed against rabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, equine herpes virus such as EHV-1 or EHV4, Ehrlichia risticii, Streptococcus equi , tetanus toxoid, equine influenza virus (EIV), or the like or a combination thereof.
- the immunogenically active component of the invention may be incorporated into liposomes using known technology such as that described in Nature, 1974, 252, 252-254 or Journal of Immunology, 1978, 120, 1109-13.
- the immunogenically active component of the invention may be conjugated to suitable biological compounds such as polysaccharides, peptides, proteins, or the like, or a combination thereof.
- the inventive vaccine composition may be formulated in dosage unit form as heretofore described to facilitate administration and ensure uniformity of dosage.
- Formulation may be effected using available techniques, such as those applicable to preparations of emulsions.
- inventive vaccine composition may be administered parenterally, for example, intramuscularly, subcutaneously, intraperitoneally, intradermally or the like, preferably intramuscularly; or said composition may be administered orally or intranasally.
- the present invention also provides a method for the prevention or amelioration of West Nile encephalitis in equidae, preferably horses, which comprises administering to said equidae a safened vaccine composition as described hereinabove.
- the vaccine composition of the invention is administered parenterally, subcutaneously, orally, intranasally, or by other available means, preferably parenterally, more preferably intramuscularly, in effective amounts according to a schedule which may be determined by the time of anticipated potential exposure to a carrier of the West Nile virus.
- a typical treatment schedule or dosing regimen may include parenteral administration, preferably intramuscular injection of one dosage unit, at least about 2-8 weeks prior to potential exposure. At least two administrations are preferred, for example one dosage unit at about 8 weeks and a second dosage unit at about 3-5 weeks prior to potential exposure of the treated animal.
- a dosage unit will typically be within the range of about 0.1 to 10 milliliters of vaccine composition containing the previously described amounts of active and percentages of adjuvant and inactive(s) as set forth.
- a dosage unit within the range of about 0.5 to 5 milliliters is perhaps more preferred, with about 1 to 2 milliliter(s) being particularly preferred.
- the ingredients are mixed and homogenized until a stable mass or emulsion is formed. Prior to homogenization, the ingredients or mixture may be autoclaved. The emulsion may be further sterilized by filtration. Formalin may be added up to a final concentration of 0.2%. Thimerosal may be added to a final dilution of 1:10,000.
- the vaccines are formulated by suspending the appropriate volume of inactivated virus fluid in 1-20% by volume of SP oil per 1 mL dose.
- horses are randomly divided into four groups: one group of twenty horses is administered test vaccine at a dose of 1 ⁇ 10 7 TCID 50 (Tissue Culture Infectious Dose); a second group of twenty horses is administered test vaccine at a dose of 5 ⁇ 10 7 TCID 50 ; a third group of five horses is administered test vaccine at a dose of 1 ⁇ 10 8 TCID 50 ; and a fourth group of eight horses are maintained as non-vaccinated environmental controls.
- Treated horses are given a first dose of vaccine according to the group to which they are assigned. At twenty-one days following administration of the first dose, a second dose of the same vaccine is administered. All horses are bled for serum at the time of administration of the first and second dose and at weekly intervals through 28 days post second dose administration.
- Test Vaccine A Component Conc./Dose Volume/mL West Nile virus-Inactivated 1 ⁇ 10 7 TCID 50 0.0347 mL MEM 1 NA 0.9138 mL SP oil 5% 0.0500 mL Polymyxin B 2 30.0 mcg/mL 0.0003 mL Neomycin 30.0 mcg/mL 0.0003 mL Thimerosal (5%) 1:20,000 0.0010 mL
- Test Vaccine B Component Conc./Dose Volume/mL West Nile virus-Inactivated 5 ⁇ 10 7 TCID 50 0.1734 mL MEM NA 0.7752 mL SP oil 5% 0.0500 mL Polymyxin B 2 30.0 mcg/mL 0.0002 mL Neomycin 3 30.0 mcg/mL 0.0002 mL Thimerosal 4 (5%) 1:20,000 0.0010 mL
- Test Vaccine C Component Conc./Dose Volume/mL West Nile virus-Inactivated 1 ⁇ 10 8 TCID 50 0.3467 mL MEM 1 NA 0.6019 mL SP oil 5% 0.0500 mL Polymyxin B 2 30.0 mcg/mL 0.0002 mL Neomycin 3 30.0 mcg/mL 0.0002 mL Thimerosal 4 (5%) 1:20,000 0.0010 mL 1 LTI, Grand Island, NY 2 Sigma, St. Louis, MO 3 Sigma, St. Louis, MO 4 Sigma, St. Louis, MO
- the serological data obtained is shown in Table I below, wherein: 0 DPV 1 designates day zero, pre vaccination; and 14 DPV 2 designates day 14, post vaccination. NR designates no results.
- 648 healthy male and female horses are vaccinated with a 6 ⁇ 10 6 TCID 50 dose of inactivated test vaccine administered as a 1 mL dose vaccination by intramuscular administration and followed in three to four weeks by a second 1 mL dose vaccination.
- the treated horses are housed and fed using conventional husbandry practices for farm or stable. All treated horses are observed by a veterinarian for 30 minutes following vaccination for immediate reactions such as salivation, labored or irregular breathing, shaking, or anaphylaxis.
- the horses are observed daily for any delayed reactions such as lethargy, anorexia or unusual swelling at the injection site.
- Blood samples of 5 to 10 mL are taken by venipuncture from treated horses on the day of first vaccination (day Zero) and at least once more at two or more weeks post second vaccination (day 36 or greater). Serological assays using PRNT 5 testing are performed. 5 Chang, G. J.; Hunt, A. R. and Davis B., Journal of Virology, 74 pp 4244-5422 (2000). Test Vaccine Component Conc./Dose Volume/mL West Nile virus-Inactivated 6 ⁇ 10 8 TCID 50 0.21 mL SP oil 5% 0.05 mL MEM N/A 0.74 mL
- Horses in the vaccinated group received intramuscularly two doses of the test vaccine containing killed West Nile virus (5 ⁇ 10 7 TCID 50 per dose with 5% SP oil), influenza virus, encephalomyelitis virus (Eastern, Western and Venezuelan), rhinopneumonitis virus (serotypes 1 and 4), and tetanus toxoid, three weeks apart. Serum samples were collected periodically for antibody response measured by plaque reduction neutralization test (PRNT). Twenty-four (24) days after the second vaccination, all horses were challenged subcutaneously with WNV.
- CSF Cerebrospinal fluid
- spinal cord Cervical, thoracic, and lumbar
- brain frontal, occipital, medulla oblongata, and brain stem
- Results from this study demonstrated a significant protection against both viremia and signs of clinical WNV disease in horses vaccinated with the test combination vaccine.
- Results from this second study demonstrate a significant protection (94% of preventable fraction) against viremia in horses vaccinated with the killed monovalent WNV vaccine. These results also demonstrate a long duration of protective immunity.
- the DNA vaccine contained 100 ⁇ g of purified DNA adjuvanted with 5% SP oil per 2 mL dose, and was evaluated against experimental WNV challenge.
- bacterial cells were harvested from a culture passaged 10 times from a master seed using E. coli DH10B obtained from Invitrogen (Carlsbad, Calif.) containing a West Nile plasmid pCBWN obtained from the Centers for Disease Control (Fort Collins, Colo.).
- the bacterial cells were suspended in glucose-tris-EDTA buffer and lysed with sodium hydroxide and sodium dodecyl sulfate. The lysate was neutralized with a potassium acetate solution.
- the precipitated complex material containing DNA, RNA, cell debris and proteins was removed by filtration.
- the filtrate was precipitated with the addition of isopropyl alcohol.
- the precipitate was collected by centrifugation and resuspended in buffer. This process was repeated using ammonium acetate. The precipitate collected was resuspended in buffer and loaded into a chromatography column packed with Polyflo® resin. The column was then washed and the plasmid DNA was eluted from the column. The eluate was finally diafiltered extensively against phosphate buffer saline. The purified plasmid DNA stocks were then shipped for blending.
- the test vaccine contained 100 ⁇ g of plasmid DNA adjuvanted with 5% SP oil.
- the horses used for testing were randomly assigned into two groups: 20 animals received the WNV DNA vaccine, and 10 animals were used as controls.
- the first group were vaccinated intramuscularly with two 2.0 mL doses of vaccine three weeks apart.
- the control horses received no vaccinations or placebos.
- One group of horses (9 vaccinates and 5 controls) were challenged 5 weeks after the second vaccination, whereas a second group of horses (11 vaccinates and 5 controls) were challenged 12 weeks after the second vaccination.
- Aedes albopictus mosquitoes which had been infected with WNV 12 days prior to the horse challenge, were allowed to feed on each horse for at least 5 minutes.
- Viremia was detected in 5 of 5 control animals and 4 of 9 vaccinates in the first challenge group, whereas 4 of 5 controls and 2 of 11 vaccinates were viremic in the second challenge group of horses. The viremia detected was transient, and occurred only within the first six days after challenge. As a whole, viremia was detected in 9 out of 10 (90%) control horses, while only 6 out of 20 (30%) vaccinates were detected with viremia.
- Results from this study demonstrated a significant protection against viremia in horses vaccinated with the test vaccine.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method for the prevention or amelioration of West Nile disease, such as encephalitis, in equidae by administering the vaccine composition herein set forth.
Description
- This application claims priority from co-pending U.S. application Ser. No. 60/308,334 filed on Jul. 27, 2001.
- The present invention relates to safe and effective West Nile Virus vaccines, and to methods of administering same to mammals, in particular horses.
- Known as a Flavivirus, the West Nile virus was first identified in 1937 in Africa and first found in North America in 1999. Migratory birds are considered the primary means whereby infection is spread within and between countries. The virus is transmitted by mosquitoes that have acquired infection by feeding on viremic birds. The virus is then amplified during periods of adult mosquito blood-feeding. Infected mosquitos then transmit the virus to humans and animals upon feeding thereon.
- West Nile virus is the causative agent for West Nile Virus disease, particularly West Nile encephalitis, predominately in humans, other mammals and birds. The chief concern in both the United States and foreign countries is the lack of effective treatment for West Nile virus disease. Anti-inflammatory drugs are used to combat swelling of central nervous system tissues, but beyond that no medical intervention is available. Nor is there believed to be a suitable vaccine known to prevent the infection. To date, preventing contact with carriers appears to be the only means of controlling the West Nile virus.
- What is therefore needed in the art is to provide a safe and effective equine West Nile virus vaccine composition. The vaccine composition should be sufficiently safened so as to be suitable for administration even to pregnant mares without adverse effect.
- Also needed is a method for the prevention or amelioration of West Nile Virus disease, particularly West Nile encephalitis, in equidae and other mammals.
- The present invention provides a safened vaccine composition which comprises: an effective immunizing amount of an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, and a mixture thereof; an immunogenically stimulating amount of a metabolizable oil; and a pharmacologically acceptable carrier.
- The present invention also provides a method for the prevention or amelioration of West Nile encephalitis in equidae which comprises administering to said equidae a safened vaccine composition which comprises an effective immunizing amount of an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, and a mixture thereof; an immunogenically stimulating amount of a metabolizable oil; and a pharmacologically acceptable carrier.
- Also provided as part of the invention is a safe and effective West Nile Virus vaccine suitable for use in horses which comprises an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, and a mixture thereof; an immunogenically stimulating amount of a metabolizable oil; and a pharmacologically acceptable carrier.
- In a further embodiment, the invention describes a vaccine composition comprising at least about at least about 1×104 TCID50 per unit dose of inactivated West Nile virus, or a component thereof, and about 4% to 10% vol/vol of a metabolizable oil comprising about 1 to 3% polyoxyethylene-polyoxypropylene block copolymer, about 2 to 6% of squalane and about 0.1 to 0.5% of polyoxyethylene sorbitan monooleate.
- Further provided is a safened and effective West Nile virus vaccine for equidae, comprising at least about 1×106 TCID50 per unit dose of killed or inactivated West Nile virus, and at least about 1% vol/vol of an adjuvant comprising at least one metabolizable oil and at least one wetting or dispersing agent.
- The invention also sets forth a vaccine regimen for horses, comprising two dosage units of killed or inactivated West Nile virus, wherein each said dosage unit comprises about 0.5 to 5 milliliters of a composition containing at least about 5×107 TCID50 of said virus and about 1 to 10% vol/vol of an adjuvant, said adjuvant comprising at least one metabolizable oil and at least two nonionic surfactants, and further wherein said dosage unit comprises a pharmacologically acceptable carrier.
- Also provided as part of the invention is an equine vaccine containing West Nile plasmid DNA in an amount of about 50 to 3,000 micrograms per dose, together with one or more adjuvants and a suitable carrier. A vaccine regimen would comprise administering at least about one dose of this composition, and desirably at least about 2 doses, to horses for immunization against West Nile virus disease.
- Further, objects and features of the invention will become apparent from the detailed description and the claims set forth herein below.
- Scientists believe that the West Nile virus follows the same pattern of infection found with other mosquito-transmitted viruses. When an infected mosquito bites an equid, the virus enters the skin or tissues just below the bite site, where it is picked up by the circulation. The virus can multiply in the bloodstream, and the equid may develop a fever, which often goes undetected because there are no other signs of illness at the time. However, once the virus has invaded the nervous system, clinical signs appear within one to three days. Most affected equidae, such as horses, first exhibit signs of posterior weakness or paralysis and poor coordination. Depression and related behavior changes may accompany the physical changes. In severe cases, tremors, convulsions, paddling of the limbs and paralysis may develop. Severe neurological problems and mortality have also been observed. To date, no vaccine known to prevent West Nile virus in equidae is available; and the only means of controlling the West Nile virus appears to be the prevention of contact with a carrier.
- It has now been found that a safe and effective vaccine composition which comprises an effective immunizing amount of an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, plasmid West Nile virus DNA, plasmid with sequence inserts of said virus, and a mixture thereof; an immunogenically stimulating amount of an adjuvant, in particular a metabolizable oil; and a pharmacologically acceptable carrier may be administered to equidae, particularly horses, to prevent or ameliorate West Nile Virus disease such as encephalitis.
- DNA derived from the West Nile virus may be obtained via isolation from sources such as the fluids or tissues of equine or avian species diagnosed to have West Nile encephalitis. Such sources include cerebral spinal fluid or sections of spinal cord or brain. DNA may also be obtained using other available techniques such as plasmid technology. For example, suitable cells of an organism, e.g. E. coli, may be transformed with a plasmid containing West Nile protein sequence inserts to obtain a master seed. The master seed may then be cultured and passaged. Transformed cells containing the West Nile DNA may then be harvested, and the DNA isolated and obtained using techniques available to the skilled artisan.
- Whole or subunit West Nile virus may be isolated from infected animals using conventional techniques. Samples of the virus may also be obtained from tissue culture collections which maintain a depository for organisms such as West Nile. At the American Type Culture Collection (ATCC), for example, the West Nile virus has been deposited under ATCC No.s VR-82, VR-1267 and VR-1267 AF.
- Whole or subunit West Nile virus may be inactivated by conventional inactivating means, for example chemical inactivation using chemical inactivating agents such as binary ethyleneimine, beta-propiolactone, formalin, gluteraldehyde, sodium dodecyl sulfate, or the like or a mixture thereof, preferably formalin. Said virus may also be inactivated by heat or psoralen in the presence of ultraviolet light. (Live, attenuated West Nile virus may also be used in certain embodiments, but this is perhaps much less preferred.)
- Whole or subunit West Nile virus may be maintained or grown in mouse brains or in suitable tissue culture media, such as optiMEM (LTI, Grand Island, N.Y.) or MEM media, or in cells known in the art such as African green monkey kidney (Vero) cells or baby hamster (BHK) cells, preferably Vero cells. Said virus may then be separated from the tissue culture or cell media using conventional techniques such as centrifugation, filtration or the like.
- A preferred West Nile virus isolate may be obtained from the National Veterinary Services Laboratory (part of the United States Department of Agriculture) in Ames, Iowa as strain VM-2. The virus strain may be plaque purified up to three times, and passaged to X+5 in Vero cells.
- As used herein the term “immunogenically active” designates the ability to stimulate an immune response, i.e., to stimulate the production of antibodies, particularly humoral antibodies, or to stimulate a cell-mediated response. For example, the ability to stimulate the production of circulating or secretory antibodies or the production of a cell-mediated response in local mucosal regions, (e.g., intestinal mucosa), peripheral blood, cerebral spinal fluid or the like.
- The effective immunizing amount of the immunogenically active component may vary and may be any amount sufficient to evoke an immune response and provide immunological protection against West Nile Virus disease. Amounts wherein a dosage unit comprises at least about 1×104 TCID50 of killed or inactivated whole or subunit virus cells or antigen or DNA cells derived therefrom or a mixture thereof, preferably at least about 1×106 TCID50, are suitable. Even more preferably, at least about 1×107 TCID50 per dosage unit may be utilized. It is especially desirable that at least about 5×107 TCID50 of killed or inactivated whole or subunit West Nile virus cells or antigen or DNA cells derived therefrom or a mixture thereof be used in the vaccine composition of the invention. In certain embodiments, as much as 1×109 TCID50 and more may be utilized. A range of about 1×104 TCID50 to about 1×108 TCID50 may also be utilized.
- In a further embodiment of the invention, it is contemplated that about 50 to 3,000 micrograms (μg or 10−6 grams) of West Nile plasmid DNA may be utilized in one dosage unit of the vaccine composition. More preferably, about 100 to 1,000 μg may be used, with about 100 to 250 μg of plasmid DNA being more preferred.
- At least one dosage unit per animal is contemplated herein as a vaccination regimen. In some embodiments, two or more dosage units may be especially useful. A dosage unit may typically be about 0.1 to 10 milliliters of vaccine composition, preferably about 0.5 to 5 milliliters, and even more preferably about 1 to 2 milliliters, with each dosage unit containing the heretofore described quantity of virus or virus component. The skilled artisan will quickly recognize that a particular quantity of vaccine composition per dosage unit, as well as the total number of dosage units per vaccination regimen, may be optimized, so long as an effective immunizing amount of the virus or a component thereof is ultimately delivered to the animal.
- The West Nile virus vaccine composition of the invention may also contain one or more adjuvants. As used herein the term “adjuvant” refers to any component which improves the body's response to a vaccine. The adjuvant will typically comprise about 0.1 to 50% vol/vol of the vaccine formulation of the invention, more preferably about 1 to 50% of the vaccine, and even more desirably about 1 to 20% thereof. Amounts of about 4 to 10% may be even more preferred.
- Suitable adjuvants can include immunostimulating oils such as certain metabolizable oils. Metabolizable oils suitable for use in the composition of the invention include oil emulsions, e.g., SP oil (hereinafter described), Emulsigen (MPV Laboratories, Ralston, NZ), Montanide 264,266,26 (Seppic SA, Paris, France), as well as peanut oil and other vegetable-based oils, squalane (shark liver oil) or other metabolizable oil which can be shown to be suitable as an adjuvant in veterinary vaccine practice.
- In addition, the adjuvant may include one or more wetting or dispersing agents in amounts of about 0.1 to 25%, more preferably about 1 to 10%, and even more preferably about 1 to 3% by volume of the adjuvant. Particularly preferred as wetting or dispersing agents are non-ionic surfactants. Useful non-ionic surfactants include polyoxyethylene/polyoxypropylene block copolymers, especially those marketed under the trademark PLURONIC® and available from BASF Corporation (Mt. Olive, N.J.). Other useful nonionic surfactants include polyoxyethylene esters such as polyoxyethylene sorbitan monooleate, available under the trademark TWEEN 80®. It may be desirable to include more than one, e.g. at least two, wetting or dispersing agents in the adjuvant as part of the vaccine composition of the invention.
- Other components of the adjuvant may include such preservative compounds as formalin and thimerosal in amounts of up to about 1% vol/vol of the adjuvant.
- As an adjuvant, SP oil is preferred. As used in the specification and claims, the term “SP oil” designates an oil emulsion comprising a polyoxyethylene-polyoxypropylene block copolymer, squalane, polyoxyethylene sorbitan monooleate and a buffered salt solution. In general, the SP oil emulsion will comprise about 1 to 3% vol/vol of block copolymer, about 2 to 6% vol/vol of squalane, more particularly about 3 to 6% of squalane, and about 0.1 to 0.5% vol/vol of polyoxyethylene sorbitan monooleate, with the remainder being a buffered salt solution.
- When utilized, immunogenically stimulating amounts of SP oil as adjuvant in the vaccine composition of the invention may vary according to the immunogenically active component, the degree of potential infectious exposure, method of administration of the vaccine composition, the age and size of the equid, or the like. In general, amounts of about 1% to 50% vol/vol, preferably about 4% to 10% vol/vol, and more preferably about 4% to 5% vol/vol of SP oil are suitable.
- In general, it is believed that a live virus vaccine may potentially lack sufficient safety in a given target host, and that a killed or inactivated virus vaccine may potentially lack the ability to stimulate a sufficiently effective immunologic response. Commonly, an adjuvant or immunogenically stimulating compound is used in combination with a killed or inactivated virus in a vaccine composition to obtain acceptable efficacy. However, safety to the target host is often compromised by the addition of an adjuvant. For example, pregnant animals many times have been known to have a significantly higher rate of miscarriage after being administered a killed or inactivated virus vaccine that contains an adjuvant.
- It has now been found that when a suitable adjuvant, e.g. a metabolizable oil preferably such as SP oil, is used in combination with an immunogenically active component as described hereinabove, the resultant West Nile vaccine composition is safened for use in equidae, particularly horses, even for use in pregnant mares, while demonstrating important efficacy as well. Thus, the invention achieves the concomitant goals of effective immunization and safety, especially for pregnant animals. This combination of active immunogen and adjuvant is unheralded in the art.
- Pharmacologically acceptable carriers suitable for use in the vaccine composition of the invention may be any conventional liquid carrier suitable for veterinary pharmaceutical compositions, preferably a balanced salt solution or other water-based solution suitable for use in tissue culture media. Other available carriers may also be utilized.
- Additional excipients available in the art may also be included in the vaccine composition according to the various embodiments heretofore described. For example, pH modifiers may be utilized.
- The components of the vaccine composition of the invention as heretofore described, including the carrier, may be combined together using available techniques.
- In addition to the immunogenically active component of West Nile virus as described hereinabove as active ingredient, it is contemplated that the vaccine composition of the invention may also contain other active components such as an antipathogenic component directed against rabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, equine herpes virus such as EHV-1 or EHV4, Ehrlichia risticii, Streptococcus equi, tetanus toxoid, equine influenza virus (EIV), or the like or a combination thereof. The quantities of one or more of these viruses may be determined from efficacy literature in the art, or determined using available techniques.
- In one embodiment of the invention the immunogenically active component of the invention may be incorporated into liposomes using known technology such as that described in Nature, 1974, 252, 252-254 or Journal of Immunology, 1978, 120, 1109-13. In another embodiment of the invention, the immunogenically active component of the invention may be conjugated to suitable biological compounds such as polysaccharides, peptides, proteins, or the like, or a combination thereof.
- In a preferred embodiment of the invention, the inventive vaccine composition may be formulated in dosage unit form as heretofore described to facilitate administration and ensure uniformity of dosage. Formulation may be effected using available techniques, such as those applicable to preparations of emulsions.
- The inventive vaccine composition may be administered parenterally, for example, intramuscularly, subcutaneously, intraperitoneally, intradermally or the like, preferably intramuscularly; or said composition may be administered orally or intranasally.
- Accordingly, the present invention also provides a method for the prevention or amelioration of West Nile encephalitis in equidae, preferably horses, which comprises administering to said equidae a safened vaccine composition as described hereinabove.
- In actual practice, the vaccine composition of the invention is administered parenterally, subcutaneously, orally, intranasally, or by other available means, preferably parenterally, more preferably intramuscularly, in effective amounts according to a schedule which may be determined by the time of anticipated potential exposure to a carrier of the West Nile virus. In this way, the treated animal may have time to build immunity prior to the natural exposure. By way of non-limiting example, a typical treatment schedule or dosing regimen may include parenteral administration, preferably intramuscular injection of one dosage unit, at least about 2-8 weeks prior to potential exposure. At least two administrations are preferred, for example one dosage unit at about 8 weeks and a second dosage unit at about 3-5 weeks prior to potential exposure of the treated animal. As heretofore set forth, a dosage unit will typically be within the range of about 0.1 to 10 milliliters of vaccine composition containing the previously described amounts of active and percentages of adjuvant and inactive(s) as set forth. A dosage unit within the range of about 0.5 to 5 milliliters is perhaps more preferred, with about 1 to 2 milliliter(s) being particularly preferred.
- For a clearer understanding of the invention, the following examples are set forth below. These examples are merely illustrative and are not understood to limit the scope or underlying principles of the invention in any way. Indeed, various modifications of the invention, in addition to those shown and described herein, will become apparent to those skilled in the art from the following examples and the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.
-
Preparation of Vaccine A/Formulation of SP oil Ingredient Description Volume Polyoxyethylene-polyoxypropylene block copolymer 20.0 ml (Pluronic ® L121, BASF, Mt. Olive, NJ) Squalane (Kodak, Rochester, NY) 40.0 ml Polyoxyethylenesorbitan monooleate 3.2 ml (Tween ® 80, Sigma Chemical, St. Louis, MO) Buffered salt solution 936.8 ml (D-V PBS Solution, Ca, Mg free) - The ingredients are mixed and homogenized until a stable mass or emulsion is formed. Prior to homogenization, the ingredients or mixture may be autoclaved. The emulsion may be further sterilized by filtration. Formalin may be added up to a final concentration of 0.2%. Thimerosal may be added to a final dilution of 1:10,000.
- B/Vaccine Preparation
- An equine isolate of West Nile virus, obtained from USDA facilities in Ames, Iowa (Lot No. VM-2, Equine Origin, 1999 North American isolate, second passage in VeroM cell culture), was cultivated in multiple cultures of Vero cells in OptiMEM (LTI, Grand Island, N.Y.) tissue culture medium at 37° C. The harvests are titrated and then inactivated by means of addition of a 10% formalin solution to a final concentration of 0.1%. This is allowed to inactivate at 37° C. for a period of no less than 144 hours. Then, another addition of 0.1% formalin is added and incubated at 37° C. for another period of no less than 144 hours.
- The vaccines are formulated by suspending the appropriate volume of inactivated virus fluid in 1-20% by volume of SP oil per 1 mL dose.
- In this evaluation, horses are randomly divided into four groups: one group of twenty horses is administered test vaccine at a dose of 1×107 TCID50 (Tissue Culture Infectious Dose); a second group of twenty horses is administered test vaccine at a dose of 5×107 TCID50; a third group of five horses is administered test vaccine at a dose of 1×108 TCID50; and a fourth group of eight horses are maintained as non-vaccinated environmental controls. Treated horses are given a first dose of vaccine according to the group to which they are assigned. At twenty-one days following administration of the first dose, a second dose of the same vaccine is administered. All horses are bled for serum at the time of administration of the first and second dose and at weekly intervals through 28 days post second dose administration.
Test Vaccine A Component Conc./Dose Volume/mL West Nile virus-Inactivated 1 × 107 TCID50 0.0347 mL MEM1 NA 0.9138 mL SP oil 5% 0.0500 mL Polymyxin B2 30.0 mcg/mL 0.0003 mL Neomycin 30.0 mcg/mL 0.0003 mL Thimerosal (5%) 1:20,000 0.0010 mL -
Test Vaccine B Component Conc./Dose Volume/mL West Nile virus-Inactivated 5 × 107 TCID50 0.1734 mL MEM NA 0.7752 mL SP oil 5% 0.0500 mL Polymyxin B2 30.0 mcg/mL 0.0002 mL Neomycin3 30.0 mcg/mL 0.0002 mL Thimerosal4 (5%) 1:20,000 0.0010 mL -
Test Vaccine C Component Conc./Dose Volume/mL West Nile virus-Inactivated 1 × 108 TCID50 0.3467 mL MEM1 NA 0.6019 mL SP oil 5% 0.0500 mL Polymyxin B2 30.0 mcg/mL 0.0002 mL Neomycin3 30.0 mcg/mL 0.0002 mL Thimerosal4 (5%) 1:20,000 0.0010 mL
1LTI, Grand Island, NY
2Sigma, St. Louis, MO
3Sigma, St. Louis, MO
4Sigma, St. Louis, MO
- The serological data obtained is shown in Table I below, wherein: 0 DPV 1 designates day zero, pre vaccination; and 14 DPV 2 designates day 14, post vaccination. NR designates no results.
- As can be seen from the data on Table I, treated horses from all groups showed significant increases in antibodies to West Nile virus while the control horses maintained a non-detectable antibody level. The level of response in the horses that received vaccine was independent of the level of antigen in the vaccine that they received.
TABLE I Test Dose Test #1 Test #2 Vaccine (TC1D50) 0DPV1 14DPV2 0DPV1 14DPV2 A 1 × 107 <10 160 <10 80 A 1 × 107 <10 20 <10 10 A 1 × 107 <10 ≧320 <10 40 A 1 × 107 <10 80 <10 ≧320 A 1 × 107 <10 80 <10 40 A 1 × 107 <10 80 <10 160 A 1 × 107 <10 40 <10 40 A 1 × 107 <10 80 <10 80 A 1 × 107 <10 160 <10 80 A 1 × 107 <10 40 <10 10 A 1 × 107 <10 40 <10 10 A 1 × 107 <10 160 <10 40 A 1 × 107 <10 ≧320 <10 NR* A 1 × 107 <10 ≧320 <10 NR A 1 × 107 <10 ≧320 <10 80 A 1 × 107 <10 160 <10 20 A 1 × 107 ≧20 ≧320 <10 160 A 1 × 107 <10 80 <10 80 A 1 × 107 <10 80 <10 160 A 1 × 107 <10 160 <10 160 B 5 × 107 <10 80 <10 40 B 5 × 107 <10 20 <10 <10 B 5 × 107 <10 ≧320 <10 160 B 5 × 107 <10 80 <10 ≧320 B 5 × 107 <10 ≧320 <10 160 B 5 × 107 <10 80 <10 80 B 5 × 107 <10 160 <10 ≧320 B 5 × 107 <10 80 <10 40 B 5 × 107 <10 160 <10 40 B 5 × 107 <10 40 <10 80 B 5 × 107 <10 20 <10 20 B 5 × 107 <10 ≧320 <10 160 B 5 × 107 <10 ≧40 <10 ≧320 B 5 × 107 <10 80 <10 40 B 5 × 107 <10 80 <10 NR B 5 × 107 <20 ≧320 <10 80 B 5 × 107 ≧20 160 <10 80 B 5 × 107 <10 ≧320 <10 160 B 5 × 107 <10 ≧320 <10 ≧320 B 5 × 107 <10 80 <10 160 C 1 × 108 <10 ≧320 <10 ≧320 C 1 × 108 <10 ≧320 <10 160 C 1 × 108 <10 160 <10 80 C 1 × 108 <10 ≧320 <10 NR C 1 × 108 <10 40 <10 40 Control 0 <10 <10 <10 <10 Control 0 <10 <10 <10 <10 Control 0 <10 <10 <10 <10 Control 0 <10 <10 <10 NR Control 0 <10 <10 <10 <10 Control 0 <10 <10 <10 <10 Control 0 <10 <10 <10 <10 Control 0 <10 <10 <10 <10 - In this evaluation, 648 healthy male and female horses, including 32 pregnant mares, are vaccinated with a 6×106 TCID50 dose of inactivated test vaccine administered as a 1 mL dose vaccination by intramuscular administration and followed in three to four weeks by a second 1 mL dose vaccination. The treated horses are housed and fed using conventional husbandry practices for farm or stable. All treated horses are observed by a veterinarian for 30 minutes following vaccination for immediate reactions such as salivation, labored or irregular breathing, shaking, or anaphylaxis. For two weeks post-vaccination, the horses are observed daily for any delayed reactions such as lethargy, anorexia or unusual swelling at the injection site. Blood samples of 5 to 10 mL are taken by venipuncture from treated horses on the day of first vaccination (day Zero) and at least once more at two or more weeks post second vaccination (day 36 or greater). Serological assays using PRNT5 testing are performed.
5Chang, G. J.; Hunt, A. R. and Davis B., Journal of Virology, 74 pp 4244-5422 (2000).
Test Vaccine Component Conc./Dose Volume/mL West Nile virus-Inactivated 6 × 108 TCID50 0.21 mL SP oil 5% 0.05 mL MEM N/A 0.74 mL - No vaccine-induced safety problems were found in any of the vaccinates, including the pregnant mares. This evaluation demonstrates that the vaccine of the invention is safe for use in horses under field conditions.
- The efficacy of a combination vaccine containing killed West Nile virus (WNV) against experimental WNV challenge was evaluated.
- A total of 30 horses were allotted into one vaccinated group (20 horses) and one control group (10 horses). Horses in the vaccinated group received intramuscularly two doses of the test vaccine containing killed West Nile virus (5×107 TCID50 per dose with 5% SP oil), influenza virus, encephalomyelitis virus (Eastern, Western and Venezuelan), rhinopneumonitis virus (serotypes 1 and 4), and tetanus toxoid, three weeks apart. Serum samples were collected periodically for antibody response measured by plaque reduction neutralization test (PRNT). Twenty-four (24) days after the second vaccination, all horses were challenged subcutaneously with WNV. After challenge, horses were monitored for rectal temperature and any clinical signs twice daily for two weeks and once weekly thereafter for detection of viremia. Horses were euthanized and necropsied on 21 and 22 DPC. Cerebrospinal fluid (CSF), spinal cord (cervical, thoracic, and lumbar) and brain (frontal, occipital, medulla oblongata, and brain stem) tissue samples were examined for gross pathology and collected for virus isolation.
- Fourteen days after the second vaccination, 75% of vaccinated animals seroconverted (titer≧5) with a geometric mean titer of 10 while control animals remained negative (titer<5). The vaccination conferred a significant protection against viremia (a precursor to development of full-blown West Nile Virus disease). Nine out of 10 (90%) controls developed viremia after challenge, while only eight out of 20 (40%) vaccinates had transient viremia, or viremia lasting only a few days at most. Importantly, no WNV disease clinical signs were observed in any of the challenged vaccinated animals throughout the observation period. (Transient febrile responses were observed in one control and two vaccinated horses. However, there was no evidence to suggest these responses were due to WNV infection.) Petechial hemorrhage in white matter and subdural hemorrhage were found in the brain tissue from one control animal. WNV was isolated from the brain but not from CSF and spinal cord samples collected from this animal. No WNV was isolated from any of the tissue samples collected from other challenged horses.
- Results from this study demonstrated a significant protection against both viremia and signs of clinical WNV disease in horses vaccinated with the test combination vaccine.
- A second study has conducted with a protocol similar to that above, except that a monovalent WNV vaccine (WNV vaccine alone) was utilized, and all horses were challenged with WNV at 12 months after the second vaccination. Nine out of 11 (81.8%) of the controls developed viremia after challenge, while only one out of 19 (5.3%) of the vaccinates had transient viremia. No WNV associated clinical signs were observed in any of the challenged animals throughout the observation period. No febrile responses were observed in any of the challenged horses. No WNV was isolated from any of the tissue or CSF samples collected from any of the challenged horses. (Prior to challenge at the end of the 12 month period, 17 of the nineteen vaccinated horses had plaque reduction neutralization test (PRNT) titers of 5 or greater, while the control group remained negative (<5).)
- Results from this second study demonstrate a significant protection (94% of preventable fraction) against viremia in horses vaccinated with the killed monovalent WNV vaccine. These results also demonstrate a long duration of protective immunity.
- This example demonstrates the efficacy of a West Nile Virus (WNV) DNA vaccine, as part of a further embodiment of the invention. The DNA vaccine contained 100 μg of purified DNA adjuvanted with 5% SP oil per 2 mL dose, and was evaluated against experimental WNV challenge.
- For the composition of the WNV DNA vaccine, bacterial cells were harvested from a culture passaged 10 times from a master seed using E. coli DH10B obtained from Invitrogen (Carlsbad, Calif.) containing a West Nile plasmid pCBWN obtained from the Centers for Disease Control (Fort Collins, Colo.). The bacterial cells were suspended in glucose-tris-EDTA buffer and lysed with sodium hydroxide and sodium dodecyl sulfate. The lysate was neutralized with a potassium acetate solution. The precipitated complex material containing DNA, RNA, cell debris and proteins was removed by filtration. The filtrate was precipitated with the addition of isopropyl alcohol. The precipitate was collected by centrifugation and resuspended in buffer. This process was repeated using ammonium acetate. The precipitate collected was resuspended in buffer and loaded into a chromatography column packed with Polyflo® resin. The column was then washed and the plasmid DNA was eluted from the column. The eluate was finally diafiltered extensively against phosphate buffer saline. The purified plasmid DNA stocks were then shipped for blending. The test vaccine contained 100 μg of plasmid DNA adjuvanted with 5% SP oil.
- The horses used for testing were randomly assigned into two groups: 20 animals received the WNV DNA vaccine, and 10 animals were used as controls. The first group were vaccinated intramuscularly with two 2.0 mL doses of vaccine three weeks apart. The control horses received no vaccinations or placebos. One group of horses (9 vaccinates and 5 controls) were challenged 5 weeks after the second vaccination, whereas a second group of horses (11 vaccinates and 5 controls) were challenged 12 weeks after the second vaccination. Briefly, Aedes albopictus mosquitoes which had been infected with WNV 12 days prior to the horse challenge, were allowed to feed on each horse for at least 5 minutes. Following challenge, only those mosquitoes which were found to have engorged with blood meals from each horse were frozen at −20° C., and the virus load was titrated as a pool subsequently. Mosquitoes were then homogenized by vortexing using diluent. The homogenate was centrifuged and the supernatant was removed for titration on Vero cells.
- After challenge, rectal temperatures were taken twice daily for at least 9 days and clinical signs were monitored twice a day for at least 21 days. Serum samples were taken twice a day for the first 9 days post challenge (DPC); once daily from 10 to 14 DPC and finally at 21 DPC. Virus isolation was performed on serum samples from 0 DPC to 10 DPC for the first challenge group and from 0 DPC to 11 DPC for the second challenge group. The first group of 14 horses and the second group of 16 horses were euthanized and necropsied 28 to 37 DPC and 29 to 38 DPC, respectively. Cerebrospinal fluid (CSF) and tissue samples from the cerebrum, cerebellum and the brain stem were collected for gross pathology and virus isolation.
- At 14 days post second vaccination, 6 of 20 vaccinated had a measurable titer of 2 or greater, and one horse had a titer of 5. Vaccination had conferred protection against experimental West Nile challenge using mosquitoes. Viremia was detected in 5 of 5 control animals and 4 of 9 vaccinates in the first challenge group, whereas 4 of 5 controls and 2 of 11 vaccinates were viremic in the second challenge group of horses. The viremia detected was transient, and occurred only within the first six days after challenge. As a whole, viremia was detected in 9 out of 10 (90%) control horses, while only 6 out of 20 (30%) vaccinates were detected with viremia.
- No neurological signs attributable to WNV infection were observed in any of the study horses throughout the challenge observation period. No WNV was isolated from any of the tissue samples collected from any of the study horses. One horse from the first challenge group which was euthanized on 7 DPC showed no gross or microscopic evidence of encephalitis or meningitis.
- Results from this study demonstrated a significant protection against viremia in horses vaccinated with the test vaccine.
Claims (41)
1. A safened vaccine composition which comprises: an effective immunizing amount of an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, and a mixture thereof; an immunogenically stimulating amount of a metabolizable oil; and a pharmacologically acceptable carrier.
2. The composition according to claim 1 wherein the immunogenically active component is an inactivated whole or subunit West Nile virus, and further wherein a dosage unit of said vaccine comprises about 1×104 TCID50 to about 1×108 TCID50 of said virus.
3. The composition according to claim 1 wherein the metabolizable oil is SP oil.
4. The composition according to claim 2 wherein the immunogenically active component is an inactivated whole West Nile virus.
5. The composition according to claim 3 wherein said oil is present in the amount of about 4% to 10% vol/vol.
6. The composition according to claim 4 wherein said virus is present in sufficient quantity to provide at least about 1×104 TCID50 per unit dose of said composition.
7. The composition according to claim 5 wherein said oil is present in the amount of about 5% vol/vol.
8. The composition according to claim 7 wherein said virus is present in sufficient quantity to provide at least about 1×106 TCID50 per unit dose.
9. The composition according to claim 8 wherein said virus is inactivated whole West Nile virus.
10. A method for the prevention or amelioration of West Nile encephalitis in equidae which comprises administering to said equidae a safened vaccine composition which comprises an effective immunizing amount of an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, and a mixture thereof; an immunogenically stimulating amount of a metabolizable oil; and a pharmacologically acceptable carrier.
11. The method according to claim 10 having said vaccine composition wherein the immunogenically active component is an inactivated whole or subunit West Nile virus.
12. The method according to claim 10 having said vaccine composition wherein the metabolizable oil is SP oil.
13. The method according to claim 10 wherein said equidae are horses.
14. The method according to claim 13 wherein said horses are pregnant mares.
15. The method according to claim 10 wherein said vaccine composition is administered parenterally.
16. The method according to claim 10 wherein said vaccine composition is administered intramuscularly.
17. The method according to claim 12 having a vaccine composition wherein the immunogenically active component is inactivated whole West Nile virus.
18. The method according to claim 17 wherein said virus is present in an amount sufficient to provide at least about 1×104 TCID50 and up to about 1×109 TCID50 per unit dose.
19. The method according to claim 18 wherein said virus is present in an amount sufficient to provide at least about 1×106 TCID50 per unit dose, and at least two doses are administered to each said equidae.
20. The method according to claim 19 wherein the metabolizable oil is SP oil and is present in an amount of about 5% vol/vol.
21. The composition according to claim 6 further comprising another vaccine component directed against rabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, equine herpes virus such as EHV-1 or EHV-4, Ehrlichia risticii, Streptococcus equi, tetanus toxoid, equine influenza virus (EIV).
22. A vaccine composition, comprising:
a) at least about 1×104 TCID50 and up to about 1×109 TCID50 per unit dose of inactivated West Nile virus; and
b) about 4% to 10% vol/vol of a metabolizable oil adjuvant comprising about 1 to 3% polyoxyethylene-polyoxypropylene block copolymer, about 2 to 6% of squalane and about 0.1 to 0.5% of polyoxyethylene sorbitan monooleate.
23. A safened and effective West Nile virus vaccine for equidae, comprising:
a) at least about 1×106 TCID50 to about 1×108 TCID50 per unit dose of killed or inactivated West Nile virus, and
b) at least about 1% vol/vol of an adjuvant comprising at least one metabolizable oil and at least one wetting or dispersing agent.
24. The vaccine of claim 23 , wherein said vaccine comprises at least about 1×107 TCID50 of said virus.
25. The vaccine of claim 24 , wherein said vaccine comprises at least about 5×107 TCID50 of said virus.
26. The vaccine of claim 23 , wherein said vaccine is formulated into two dosage units.
27. The vaccine of claim 23 , comprising at least about 4% of said adjuvant.
28. The vaccine of claim 27 , comprising about 4% to 10% of said adjuvant.
29. The vaccine of claim 23 , wherein said adjuvant is SP oil.
30. The vaccine of claim 23 , comprising at least two wetting or dispersing agents.
31. The vaccine of claim 30 , wherein said wetting or dispersing agents are selected from the group consisting of non-ionic surfactants.
32. The vaccine of claim 31 , wherein said non-ionic surfactants are selected from the group consisting of polyoxyethylene/polyoxypropylene block copolymers and polyoxyethylene esters.
33. A vaccine regimen for horses or other equidae, comprising two dosage units of killed or inactivated West Nile virus, wherein each said dosage unit comprises about 0.5 to 5 milliliters of a composition containing at least about 5×107 TCID50 of said virus and about 1 to 10% vol/vol of an adjuvant, said adjuvant comprising at least one metabolizable oil and at least two nonionic surfactants, and further wherein said dosage unit comprises a pharmacologically acceptable carrier.
34. The vaccine regimen of claim 33 , wherein said adjuvant is SP oil.
35. The vaccine regimen of claim 34 , wherein said SP oil comprises squalane in an amount of about 2 to 6% by weight of said adjuvant, about 1 to 3% of polyoxyethylene/polyoxypropylene block copolymer by weight of said adjuvant, and about 0.1 to 0.5% of polyoxyethylene sorbitan monooleate by weight of said adjuvant.
36. The vaccine regimen of claim 33 , further comprising a vaccine component directed to at least one member selected from the group consisting of influenza virus, Eastern, Western and Venezuelan rhinopneumonitis virus and tetanus toxoid.
37. A West Nile virus vaccine composition comprising West Nile plasmid DNA in an amount of about 50 to 3,000 micrograms per dose.
38. The composition of claim 37 , wherein said composition comprises about 100 to 1,000 micrograms per dose.
39. The composition of claim 38 , wherein said composition comprises about 100 to 250 micrograms per dose.
40. A West Nile virus vaccine regimen which comprises administering to a horse at least about one dose of the composition of claim 37 .
41. The regimen of claim 40 , which comprises administering at least about two doses.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/589,516 US20070166325A1 (en) | 2001-07-27 | 2006-10-30 | West Nile vaccine |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30833401P | 2001-07-27 | 2001-07-27 | |
US10/202,716 US7153513B2 (en) | 2001-07-27 | 2002-07-25 | West nile vaccine |
US11/589,516 US20070166325A1 (en) | 2001-07-27 | 2006-10-30 | West Nile vaccine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/202,716 Division US7153513B2 (en) | 2001-07-27 | 2002-07-25 | West nile vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070166325A1 true US20070166325A1 (en) | 2007-07-19 |
Family
ID=27613166
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/202,716 Expired - Lifetime US7153513B2 (en) | 2001-07-27 | 2002-07-25 | West nile vaccine |
US11/589,507 Expired - Lifetime US7648705B2 (en) | 2001-07-27 | 2006-10-30 | Methods for prevention or amelioration of West Nile encephalitis using a West Nile DNA vaccine |
US11/589,516 Abandoned US20070166325A1 (en) | 2001-07-27 | 2006-10-30 | West Nile vaccine |
US11/589,528 Expired - Lifetime US7648706B2 (en) | 2001-07-27 | 2006-10-30 | West nile DNA vaccine |
US11/589,515 Abandoned US20070166324A1 (en) | 2001-07-27 | 2006-10-30 | West Nile vaccine |
US11/589,595 Abandoned US20070231350A1 (en) | 2001-07-27 | 2006-10-30 | West Nile vaccine |
US11/589,523 Abandoned US20070166326A1 (en) | 2001-07-27 | 2006-10-30 | West Nile vaccine |
US11/589,527 Expired - Lifetime US7445787B2 (en) | 2001-07-27 | 2006-10-30 | Methods for preventing or ameliorating West Nile encephalitis |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/202,716 Expired - Lifetime US7153513B2 (en) | 2001-07-27 | 2002-07-25 | West nile vaccine |
US11/589,507 Expired - Lifetime US7648705B2 (en) | 2001-07-27 | 2006-10-30 | Methods for prevention or amelioration of West Nile encephalitis using a West Nile DNA vaccine |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/589,528 Expired - Lifetime US7648706B2 (en) | 2001-07-27 | 2006-10-30 | West nile DNA vaccine |
US11/589,515 Abandoned US20070166324A1 (en) | 2001-07-27 | 2006-10-30 | West Nile vaccine |
US11/589,595 Abandoned US20070231350A1 (en) | 2001-07-27 | 2006-10-30 | West Nile vaccine |
US11/589,523 Abandoned US20070166326A1 (en) | 2001-07-27 | 2006-10-30 | West Nile vaccine |
US11/589,527 Expired - Lifetime US7445787B2 (en) | 2001-07-27 | 2006-10-30 | Methods for preventing or ameliorating West Nile encephalitis |
Country Status (25)
Country | Link |
---|---|
US (8) | US7153513B2 (en) |
EP (3) | EP1427444B1 (en) |
JP (2) | JP4718778B2 (en) |
KR (2) | KR20090053967A (en) |
CN (2) | CN1273189C (en) |
AU (1) | AU2002365244B2 (en) |
BE (1) | BE2014C006I2 (en) |
BR (1) | BRPI0211492B1 (en) |
CA (1) | CA2452545C (en) |
CY (1) | CY2014010I2 (en) |
DK (1) | DK1427444T3 (en) |
ES (1) | ES2435095T3 (en) |
FR (1) | FR14C0016I2 (en) |
HK (1) | HK1066470A1 (en) |
HR (1) | HRP20040195B1 (en) |
HU (2) | HU228690B1 (en) |
LU (1) | LU92348I2 (en) |
ME (1) | ME00491B (en) |
MX (1) | MXPA04000680A (en) |
NZ (3) | NZ570270A (en) |
PL (2) | PL220846B1 (en) |
PT (1) | PT1427444E (en) |
RS (1) | RS53184B (en) |
WO (1) | WO2003061555A2 (en) |
ZA (1) | ZA200401596B (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7425437B2 (en) * | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
NZ570270A (en) * | 2001-07-27 | 2010-08-27 | Wyeth Corp | West nile vaccine for equidae |
WO2005024427A2 (en) * | 2003-09-09 | 2005-03-17 | Idexx Laboratories, Inc. | Detection of west nile virus infection and vaccination |
US7074555B2 (en) * | 2004-04-28 | 2006-07-11 | Idexx Laboratories, Inc. | Detection of West Nile Virus |
FR2870126B1 (en) | 2004-05-17 | 2009-07-17 | Pasteur Institut | RECOMBINANT LENTIVIRAL VECTOR FOR EXPRESSION OF FLAVIVIRIDAE PROTEIN AND ITS APPLICATIONS AS VACCINE |
CA2582534A1 (en) | 2004-09-09 | 2006-03-16 | Research Development Foundation | Flavivirus variants having phenotypic variation and immunogenic compositions thereof |
JP2008534598A (en) * | 2005-04-01 | 2008-08-28 | ワイス | Use of DNA vaccines in combination with conventional vaccines to overcome immunogen interference |
US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
WO2006120230A2 (en) | 2005-05-12 | 2006-11-16 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
EP1724338A1 (en) * | 2005-05-19 | 2006-11-22 | Crucell Holland B.V. | Methods for the production of a whole-inactivated West Nile Virus vaccine |
WO2006122964A1 (en) * | 2005-05-19 | 2006-11-23 | Crucell Holland B.V. | Methods for the production of a whole-inactivated west nile virus vaccine |
RU2436591C2 (en) | 2005-06-24 | 2011-12-20 | Интервет Интернэшнл Б.В. | Inactivated chimeric vaccines and related methods of application |
MX2008005234A (en) * | 2005-10-19 | 2008-09-23 | Univ Florida | Influenza viruses able to infect canids, uses thereof. |
WO2007047728A2 (en) * | 2005-10-20 | 2007-04-26 | Wyeth | Compositions and methods for the treatment of canine influenza virus disease |
EP2026839A4 (en) * | 2005-12-14 | 2009-04-01 | Univ Oklahoma | RNA VIRUS VACCINES AND METHODS |
EA031202B1 (en) * | 2006-06-06 | 2018-11-30 | Янссен Вэксинс Энд Превеншн Б.В. | Human antibody having phagocytic activity against staphylococci and use thereof |
AU2008324780A1 (en) * | 2007-11-06 | 2009-05-14 | Pah W Llc | Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine |
US8877208B2 (en) | 2008-05-23 | 2014-11-04 | The Regents Of The University Of Michigan | Multivalent nanoemulsion vaccines |
EP2306812A4 (en) * | 2008-07-30 | 2013-02-20 | Univ Kentucky Res Found | Equine disease model for herpesvirus neurologic disease and uses thereof |
EP2334327B1 (en) * | 2008-08-29 | 2016-01-06 | Boehringer Ingelheim Vetmedica, Inc. | West nile virus vaccine |
EP2485725A2 (en) * | 2009-10-07 | 2012-08-15 | Wyeth LLC | Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof |
MX350718B (en) | 2011-03-14 | 2017-09-14 | Boehringer Ingelheim Vetmedica Inc | Equine rhinitis vaccine. |
CN103045544B (en) * | 2011-10-17 | 2015-01-14 | 华中农业大学 | Recombinant pseudotyped baculovirus Bac-G-prM/E for preventing West Nile virus as well as vaccine and application thereof |
RU2627447C2 (en) * | 2013-05-14 | 2017-08-08 | ЗОИТИС СЕРВИСЕЗ ЭлЭлСи | New vaccine compositions comprising immunostimulatory oligonucleotides |
CN105530956A (en) * | 2013-09-05 | 2016-04-27 | 硕腾服务有限责任公司 | Hendra and Nipah virus G glycoprotein immunogenic compositions |
WO2017210215A1 (en) | 2016-05-31 | 2017-12-07 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Zika virus vaccine and methods of production |
PL70842Y1 (en) * | 2017-08-25 | 2019-06-28 | Gondek Lukasz Kuznia Mocy | Device for regeneration of solid particles filters and automobile analytic converters |
AR118202A1 (en) | 2019-02-27 | 2021-09-22 | Univ Rochester | MULTIVALENT VACCINE AGAINST LIVE ATTENUATED VIRUS INFLUENZA FOR THE PREVENTION AND CONTROL OF EQUINE INFLUENZA VIRUS (EIV) IN HORSES |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
US6235282B1 (en) * | 1993-03-08 | 2001-05-22 | Rhone Merieux | Vaccinal fluid water-in-oil emulsions containing a metabolizable oil |
US20020164349A1 (en) * | 2000-10-04 | 2002-11-07 | Weiner David B. | Compositions and methods of using capsid protein from Flaviviruses and Pestiviruses |
US20030022849A1 (en) * | 1998-06-04 | 2003-01-30 | Chang Gwong-Jen J. | Nucleic acid vaccines for prevention of flavivirus infection |
US20030104008A1 (en) * | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
US7153513B2 (en) * | 2001-07-27 | 2006-12-26 | Wyeth | West nile vaccine |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US308334A (en) | 1884-11-18 | Ladder | ||
US5741696A (en) * | 1992-08-07 | 1998-04-21 | Syntro Corporation | Recombinant equine herpesviruses |
KR100374434B1 (en) * | 1994-05-10 | 2003-06-09 | 와이어쓰 | Modified Respiratory-Related Synthetic Virus (BRSV) Live Vaccine Composition |
EP1084252B1 (en) | 1998-06-04 | 2006-12-27 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Nucleic acid vaccines for prevention of flavivirus infection |
WO2002068637A2 (en) | 2000-10-20 | 2002-09-06 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-based treatment of diseases or conditions related to west nile virus infection |
WO2002083903A2 (en) | 2001-02-28 | 2002-10-24 | Brown University Research Foundation | West nile virus epitopes and uses thereof |
CA2440593A1 (en) * | 2001-03-12 | 2002-09-19 | Yale University | Compositions and methods comprising west nile virus polypeptides |
FR2823222B1 (en) * | 2001-04-06 | 2004-02-06 | Merial Sas | VACCINE AGAINST NILE FEVER VIRUS |
US7785799B2 (en) | 2002-08-16 | 2010-08-31 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain III antigens |
-
2002
- 2002-07-23 NZ NZ570270A patent/NZ570270A/en not_active Application Discontinuation
- 2002-07-23 EP EP02806585.2A patent/EP1427444B1/en not_active Expired - Lifetime
- 2002-07-23 ES ES02806585T patent/ES2435095T3/en not_active Expired - Lifetime
- 2002-07-23 RS YU8004A patent/RS53184B/en unknown
- 2002-07-23 CN CNB028146646A patent/CN1273189C/en not_active Expired - Lifetime
- 2002-07-23 PT PT2806585T patent/PT1427444E/en unknown
- 2002-07-23 KR KR1020097010065A patent/KR20090053967A/en not_active Ceased
- 2002-07-23 PL PL398575A patent/PL220846B1/en unknown
- 2002-07-23 EP EP10183676A patent/EP2283858A3/en not_active Ceased
- 2002-07-23 JP JP2003561501A patent/JP4718778B2/en not_active Expired - Lifetime
- 2002-07-23 EP EP10183615A patent/EP2281572A1/en not_active Withdrawn
- 2002-07-23 KR KR10-2004-7001202A patent/KR20040028952A/en not_active Ceased
- 2002-07-23 DK DK02806585.2T patent/DK1427444T3/en active
- 2002-07-23 BR BRPI0211492A patent/BRPI0211492B1/en active IP Right Grant
- 2002-07-23 HU HU0401606A patent/HU228690B1/en active Protection Beyond IP Right Term
- 2002-07-23 ME MEP-2008-784A patent/ME00491B/en unknown
- 2002-07-23 MX MXPA04000680A patent/MXPA04000680A/en active IP Right Grant
- 2002-07-23 CA CA2452545A patent/CA2452545C/en not_active Expired - Lifetime
- 2002-07-23 WO PCT/US2002/023447 patent/WO2003061555A2/en active Application Filing
- 2002-07-23 CN CN2006101058113A patent/CN1935258B/en not_active Expired - Lifetime
- 2002-07-23 NZ NZ531265A patent/NZ531265A/en not_active IP Right Cessation
- 2002-07-23 PL PL368535A patent/PL212212B1/en unknown
- 2002-07-23 AU AU2002365244A patent/AU2002365244B2/en not_active Expired
- 2002-07-25 US US10/202,716 patent/US7153513B2/en not_active Expired - Lifetime
-
2004
- 2004-02-26 HR HRP20040195AA patent/HRP20040195B1/en not_active IP Right Cessation
- 2004-02-26 ZA ZA2004/01596A patent/ZA200401596B/en unknown
- 2004-11-26 HK HK04109356.5A patent/HK1066470A1/en not_active IP Right Cessation
-
2006
- 2006-10-30 US US11/589,507 patent/US7648705B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,516 patent/US20070166325A1/en not_active Abandoned
- 2006-10-30 US US11/589,528 patent/US7648706B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,515 patent/US20070166324A1/en not_active Abandoned
- 2006-10-30 US US11/589,595 patent/US20070231350A1/en not_active Abandoned
- 2006-10-30 US US11/589,523 patent/US20070166326A1/en not_active Abandoned
- 2006-10-30 US US11/589,527 patent/US7445787B2/en not_active Expired - Lifetime
-
2007
- 2007-02-13 NZ NZ553165A patent/NZ553165A/en not_active IP Right Cessation
-
2010
- 2010-11-15 JP JP2010255105A patent/JP2011057692A/en active Pending
-
2013
- 2013-10-04 HU HUS1300055C patent/HUS1300055I1/en unknown
-
2014
- 2014-01-06 LU LU92348C patent/LU92348I2/en unknown
- 2014-01-31 BE BE2014C006C patent/BE2014C006I2/fr unknown
- 2014-02-20 CY CY2014010C patent/CY2014010I2/en unknown
- 2014-02-21 FR FR14C0016C patent/FR14C0016I2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
US6235282B1 (en) * | 1993-03-08 | 2001-05-22 | Rhone Merieux | Vaccinal fluid water-in-oil emulsions containing a metabolizable oil |
US20030022849A1 (en) * | 1998-06-04 | 2003-01-30 | Chang Gwong-Jen J. | Nucleic acid vaccines for prevention of flavivirus infection |
US20020164349A1 (en) * | 2000-10-04 | 2002-11-07 | Weiner David B. | Compositions and methods of using capsid protein from Flaviviruses and Pestiviruses |
US20030104008A1 (en) * | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
US7153513B2 (en) * | 2001-07-27 | 2006-12-26 | Wyeth | West nile vaccine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7648706B2 (en) | West nile DNA vaccine | |
AU2002365244A1 (en) | West nile vaccine | |
KR100374434B1 (en) | Modified Respiratory-Related Synthetic Virus (BRSV) Live Vaccine Composition | |
EP2280729A1 (en) | Inactivated live-attenuated bluetongue virus vaccine | |
AU782657B2 (en) | Vaccination against canine herpesvirus infection and vaccines | |
BR122015019697B1 (en) | west nile vaccine composition, and use of plasmid with west nile virus DNA sequence insertions in the preparation thereof | |
US20020041886A1 (en) | Equine protozoal myeloencephalitis vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |